This article contains links to products or services from one or more of our advertisers or partners. We may receive a commission when you click or make a purchase using our site. Learn more about how we make money.

How to buy Selecta Biosciences stock | $3.21

Own Selecta Biosciences stock in just a few minutes.


Fact checked

Selecta Biosciences, Inc is a biotechnology business based in the US. Selecta Biosciences shares (SELB) are listed on the NASDAQ and all prices are listed in US Dollars. Selecta Biosciences employs 39 staff and has a trailing 12-month revenue of around USD$11.3 million.

How to buy shares in Selecta Biosciences

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Selecta Biosciences. Find the stock by name or ticker symbol: SELB. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Selecta Biosciences reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$3.21, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Selecta Biosciences, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Selecta Biosciences. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Selecta Biosciences share price

Use our graph to track the performance of SELB stocks over time.

Selecta Biosciences shares at a glance

Information last updated 2020-11-27.
Latest market close USD$3.21
52-week range USD$1.42 - USD$4.83
50-day moving average USD$2.8531
200-day moving average USD$2.8068
Wall St. target price USD$6.71
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-1.845

Buy Selecta Biosciences shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Stocks, Mutual funds, ETFs, Forex
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Stocks, Options, ETFs, Cryptocurrency
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
or $25 broker-assisted
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
$0 for US stocks
Stocks, Options, ETFs
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Selecta Biosciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Selecta Biosciences price performance over time

Historical closes compared with the close of $3.21 from 2020-12-04

1 week (2020-11-25) -1.83%
1 month (2020-11-06) 5.94%
3 months (2020-09-04) 47.25%
6 months (2020-06-05) -11.57%
1 year (2019-12-05) 115.44%
2 years (2018-12-04) -43.88%
3 years (2017-12-05) -67.01%
5 years (2015-12-02) N/A

Selecta Biosciences financials

Revenue TTM USD$11.3 million
Gross profit TTM USD$-20,472,000
Return on assets TTM -34.85%
Return on equity TTM 0%
Profit margin 0%
Book value $0.097
Market capitalisation USD$371.5 million

TTM: trailing 12 months

Shorting Selecta Biosciences shares

There are currently 10.6 million Selecta Biosciences shares held short by investors – that's known as Selecta Biosciences's "short interest". This figure is 18.2% up from 8.9 million last month.

There are a few different ways that this level of interest in shorting Selecta Biosciences shares can be evaluated.

Selecta Biosciences's "short interest ratio" (SIR)

Selecta Biosciences's "short interest ratio" (SIR) is the quantity of Selecta Biosciences shares currently shorted divided by the average quantity of Selecta Biosciences shares traded daily (recently around 4.4 million). Selecta Biosciences's SIR currently stands at 2.43. In other words for every 100,000 Selecta Biosciences shares traded daily on the market, roughly 2430 shares are currently held short.

However Selecta Biosciences's short interest can also be evaluated against the total number of Selecta Biosciences shares, or, against the total number of tradable Selecta Biosciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Selecta Biosciences's short interest could be expressed as 0.09% of the outstanding shares (for every 100,000 Selecta Biosciences shares in existence, roughly 90 shares are currently held short) or 0.1047% of the tradable shares (for every 100,000 tradable Selecta Biosciences shares, roughly 105 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Selecta Biosciences.

Find out more about how you can short Selecta Biosciences stock.

Selecta Biosciences share dividends

We're not expecting Selecta Biosciences to pay a dividend over the next 12 months.

Selecta Biosciences share price volatility

Over the last 12 months, Selecta Biosciences's shares have ranged in value from as little as $1.42 up to $4.83. A popular way to gauge a stock's volatility is its "beta".

SELB.US volatility(beta: 1.19)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Selecta Biosciences's is 1.1863. This would suggest that Selecta Biosciences's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Selecta Biosciences overview

Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its proprietary pipeline includes therapeutic enzymes, gene therapies, and other products and product candidates affected by undesired immune responses. The company's lead product is SEL-212 that has completed Phase II clinical trials for the treatment of chronic refractory gout. It also engages in the development of gene therapy product candidates that are in preclinical development for rare inborn errors of metabolism, including SEL-302, a therapy program for the treatment methylmalonic academia; and SEL-313, a product candidate to treat ornithine transcarbamylase deficiency. Selecta Biosciences, Inc. has license and collaboration agreements with Spark Therapeutics; Massachusetts Institute of Technology; Shenyang Sunshine Pharmaceutical Co., Ltd.; BIND Therapeutics, Inc.; Asklepios BioPharmaceutical, Inc. Sarepta Therapeutics, Inc.; and IGAN Biosciences, Inc. Selecta Biosciences, Inc. was founded in 2007 and is headquartered in Watertown, Massachusetts.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site